

# Defective CYP11A1 does not cleave 20a,22b-DHCHOL

Jassal, B., Nakaki, T.

European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University.

The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of <u>Creative Commons Attribution 4.0 International (CC BY 4.0)</u>
<u>License</u>. For more information see our <u>license</u>.

30/04/2024

https://reactome.org Page 1

## Introduction

Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.

The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).

### Literature references

- Fabregat, A., Sidiropoulos, K., Viteri, G., Forner, O., Marin-Garcia, P., Arnau, V. et al. (2017). Reactome pathway analysis: a high-performance in-memory approach. *BMC bioinformatics*, 18, 142.
- Sidiropoulos, K., Viteri, G., Sevilla, C., Jupe, S., Webber, M., Orlic-Milacic, M. et al. (2017). Reactome enhanced pathway visualization. *Bioinformatics*, 33, 3461-3467.
- Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P. et al. (2018). The Reactome Pathway Knowledgebase. *Nucleic Acids Res, 46*, D649-D655.
- Fabregat, A., Korninger, F., Viteri, G., Sidiropoulos, K., Marin-Garcia, P., Ping, P. et al. (2018). Reactome graph data-base: Efficient access to complex pathway data. *PLoS computational biology, 14*, e1005968.

Reactome database release: 88

This document contains 1 reaction (see Table of Contents)

https://reactome.org Page 2


# Defective CYP11A1 does not cleave 20a,22b-DHCHOL

Stable identifier: R-HSA-5580269

Type: transition

Compartments: mitochondrial matrix

Diseases: congenital adrenal insufficiency



Cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) normally catalyses the side-chain cleavage of cholesterol to form pregnenolone. CYP11A1 is the active unit of a complex comprising adrenodoxin reductase (FDXR), adrenodoxin (FDX, or adrenodoxin-like protein FDX1L) (Strushkevich et al. 2011). Defects in CYP11A1 can cause Adrenal insufficiency, congenital, with 46,XY sex reversal (AICSR; MIM:613743). This is a rare disorder that can present as acute adrenal insufficiency in infancy with elevated ACTH and plasma renin activity and low or absent adrenal steroids. Although milder forms can present, associated with partial loss of enzyme activity, the severest phenotype is associated with prematurity, complete underandrogenisation and severe, early-onset adrenal failure. CYP11A1 mutations causing complete loss of function are a 6bp insertion resulting in the insertion of glycine and aspartate codons, a 1bp deletion resulting in a premature stop at 288 and the missense mutation V415E (Tajima et al. 2001, Hiort et al. 2005, Kim et al. 2008, Sahakitrungruang et al. 2010).

### Literature references

Park, HW., Grabovec, I., Usanov, S., MacKenzie, F., Cherkesova, T., Strushkevich, N. (2011). Structural basis for pregnenolone biosynthesis by the mitochondrial monooxygenase system. *Proc. Natl. Acad. Sci. U.S.A.*, 108, 10139-43.

Werner, R., Achermann, JC., Riepe, FG., Struve, D., Hiort, O., Hoppe, U. et al. (2005). Homozygous disruption of P450 side-chain cleavage (CYP11A1) is associated with prematurity, complete 46,XY sex reversal, and severe adrenal failure. *J. Clin. Endocrinol. Metab.*, 90, 538-41.

Miller, WL., Nakae, J., Tajima, T., Kouda, N., Fujieda, K. (2001). Heterozygous mutation in the cholesterol side chain cleavage enzyme (p450scc) gene in a patient with 46,XY sex reversal and adrenal insufficiency. *J. Clin. Endocrinol. Metab.*, 86, 3820-5.

Tee, MK., Miller, WL., Blackett, PR., Sahakitrungruang, T. (2011). Partial defect in the cholesterol side-chain cleavage enzyme P450scc (CYP11A1) resembling nonclassic congenital lipoid adrenal hyperplasia. *J. Clin. Endocrinol. Metab.*, 96, 792-8. 

7

## **Editions**

2014-06-06	Authored, Edited	Jassal, B.
2014-11-03	Reviewed	Nakaki, T.